Spots Global Cancer Trial Database for Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma
Official Title: Anti-PD-1 Antibody SHR-1210 (Camrelizumab) Combined With Apatinib Mesylate in the Treatment of Unresectable Sarcoma With Chemotherapy Failure: an Open, Non-randomized Phase II Clinical Study
Study ID: NCT04126993
Conditions
Study Description
Brief Summary: To observe the effectiveness of SHR-1210 (Camrelizumab) combined with apatinib in the treatment of unresectable sarcoma patients with chemotherapy failure. The main observations were progression-free survival (PFS) and progression-free control rate (PFR), followed by objective response rate (ORR) (CR+PR), disease control rate (DCR) (CR+PR+SD), and overall survival (OS). To observe the safety of SHR-1210 (Camrelizumab) combined with apatinib in the treatment of sarcoma
Detailed Description:
Eligibility
Minimum Age: 14 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Tianjin Medical University Cancer Hospital & Institute, Tianjin, Tianjin, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
